Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Diagnosis and Treatment of MPN in Real Life - Interim-Analysis of an Exploratory Chart Review on 960 ET and MF Patients in Germany

Andreas Schmidt, Christiane Bernhardt, Anette Fries, Kathleen Jentsch-Ulrich, Andreas Josting, Stephan Kreher, Marcel Reiser, H. Tilman Steinmetz, Hans Tesch, Bernhard Kaufmann, Uta Rager, Carl C. Crodel, Francesca Palandri, Florian H. Heidel

Blood (2022) 140 (Supplement 1): 9698–9699.

https://doi.org/10.1182/blood-2022-157980

Published: 2022

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3 rd Interim Analysis of the German Non-Interventional Trial RISA

Oliver Meyer, MD PhD, Martina Stauch, Dietrich Kaempfe, MD, Rudolf Schlag, Marcel Reiser, Eyck von der Heyde, Andreas Josting, Margarete Plath, Nadine Ballerstädt, Petra Stark-Lorenzen, Axel Matzdorff, MDPhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134542

Published: 2020

Journal Articles

Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).

Bastian von Tresckow, MD, Horst Müller, PhD, Dennis A. Eichenauer, MD, Jan Peter Glossmann, MD, Andreas Josting, MD, Boris Böll, MD, Beate Klimm, MD, Michael Fuchs, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2012) 120 (21): 2633.

https://doi.org/10.1182/blood.V120.21.2633.2633

Published: 2012

Journal Articles

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

Teresa V. Halbsguth, Lucia Nogová, Horst Mueller, Michal Sieniawski, Dennis A. Eichenauer, Thomas Schober, Hiltrud Nisters-Backes, Peter Borchmann, Volker Diehl, Andreas Engert, Andreas Josting

Blood (2010) 116 (12): 2026–2032.

https://doi.org/10.1182/blood-2009-11-253211

Published: 2010

Journal Articles

A Prospectively Randomized Placebo-Controlled Trial of Epoetin-α in Patients with Advanced-Stage Hodgkin Lymphoma: Final Analysis of the GHSG HD15-EPO Trial

Andreas Engert, Peter Borchmann, Michael Fuchs, Andreas Josting, Heinz Haverkamp, Volker Diehl

Blood (2008) 112 (11): 2598.

https://doi.org/10.1182/blood.V112.11.2598.2598

Published: 2008

Journal Articles

The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

Horst Mueller, Lucia Nogova, Dennis A Eichenauer, Teresa Halbsguth, Hiltrud Nisters-Backes, Thomas Schober, Hartmut Eimermacher, Peter Borchmann, Michael Fuchs, Andreas Engert, Andreas Josting

Blood (2008) 112 (11): 2600.

https://doi.org/10.1182/blood.V112.11.2600.2600

Published: 2008

Journal Articles

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)

Michal Sieniawski, Thorsten Reineke, Lucia Nogova, Andreas Josting, Beate Pfistner, Volker Diehl, Andreas Engert

Blood (2008) 111 (1): 71–76.

https://doi.org/10.1182/blood-2007-02-073544

Published: 2008

Includes: Supplemental data

Journal Articles

Late Events in Patients with Relapsed or Refractory Hodgkin’s Lymphoma Treated with an Autologous Stem Cell Transplantation.

Michal Sieniawski, MD, Andreas Josting, MD, Carmen Canals, MD, Anthony H. Goldstone, MD, Martin Gramatzki, MD, Didier Blaise, MD, Christian Gisselbrecht, MD, Charles Crawley, MD, Philippe Colombat, MD, Jean-Luc Harousseau, MD, Peter Johnson, MD, Angelo Michele Carella, MD, Anna Sureda, MD, Gerard Socie, MD, Norbert Schmitz, MD

Blood (2007) 110 (11): 834.

https://doi.org/10.1182/blood.V110.11.834.834

Published: 2007

Journal Articles

Fertility in Male Hodgkin Lymphoma Patients - A Report of German Hodgkin Study Group.

Michal Sieniawski, Dr, Thorsten Reineke, Dr, Andreas Josting, Dr, Volker Diehl, Prof, Andreas Engert, Prof

Blood (2006) 108 (11): 101.

https://doi.org/10.1182/blood.V108.11.101.101

Published: 2006

Journal Articles

Prognostic Factors and Treatment Outcome in Lymphocyte Predominant and Classical Hodgkin’s Lymphoma: A Comprehensive Analysis of the German Hodgkin Study Group.

Lucia Nogova, MD, Thorsten Reineke, Corinne Brillant, Thomas Ruediger, Prof, Hans K. Mueller-Hermelink, Prof., Henning Bredenfeld, MD, Andreas Josting, MD, Rolf P. Mueller, Prof., Volker Diehl, Prof., Andreas Engert, Prof.

Blood (2006) 108 (11): 97.

https://doi.org/10.1182/blood.V108.11.97.97

Published: 2006

Journal Articles

Rituximab Added to an Intensified Salvage Chemotherapy Program Followed by Autologous Stem Cell Transplantation Improve in Relapsed and Refractory Aggressive Non-Hodgkin-Lymphoma.

Michal Sieniawski, MD, Jan-Peter Glossmann, MD, Thorsten Reineke, PhD, Volker Diehl, MD, Andreas Engert, MD, Andreas Josting, MD

Blood (2005) 106 (11): 1150.

https://doi.org/10.1182/blood.V106.11.1150.1150

Published: 2005

Journal Articles

A New BACOPP Schedule Is Feasible and Effective in Elderly Hodgkin’s Lymphoma Patients - Interim Results of a Multicenter Phase-II Trial of the German Hodgkin Study Group (GHSG).

Lucia Nogova, MD, Michal Sieniawski, MD, Hildrud Nisters-Backes, Veronika Jennissen, MD, Volker Diehl, MD, Andreas Engert, MD, Andreas Josting, MD

Blood (2005) 106 (11): 4735.

https://doi.org/10.1182/blood.V106.11.4735.4735

Published: 2005

Journal Articles

Mortality during Treatment of Patients with Advanced Hodgkin’s Lymphoma Undergoing Dose Escalated BEACOPP Chemotherapy: An Analysis of the German Hodgkin Study Group (GHSG).

Michael Fuchs, Jeremy Franklin, Beate Klimm, Andreas Josting, Beate Pfistner, Andreas Engert, Volker Diehl

Blood (2005) 106 (11): 2668.

https://doi.org/10.1182/blood.V106.11.2668.2668

Published: 2005

Journal Articles

Leucopenia during Treatment Is a Good Prognostic Risk Factor for Patients Undergoing Chemotherapy for Hodgkin’s Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG).

Beate Klimm, Thorsten Reineke, Heinz Haverkamp, Hans T. Eich, Karolin Behringer, Andreas Josting, Beate Pfistner, Volker Diehl, Andreas Engert

Blood (2005) 106 (11): 2674.

https://doi.org/10.1182/blood.V106.11.2674.2674

Published: 2005

Journal Articles

Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).

Andreas Engert, Annette Pluetschow, Hans T. Eich, Richard Herrmann, Bernd Doerken, Lothar Kanz, Richard Greil, Jana Markova, Beate Pfistner, Andreas Josting, Konrad Mueller-Hermelink, Ralf P. Mueller, Volker Diehl

Blood (2005) 106 (11): 2673.

https://doi.org/10.1182/blood.V106.11.2673.2673

Published: 2005

Journal Articles

Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma.

Volker Diehl, Corinne Brillant, Andreas Engert, Ralf-Peter Mueller, Hans-Theodor Eich, Konrad Mueller-Hermelink, Richard Herrmann, Jana Markova, Anthony Ho, Wolfgang Hiddemann, Bernd Doerken, Richard Greil, Andreas Josting, Beate Pfistner

Blood (2005) 106 (11): 816.

https://doi.org/10.1182/blood.V106.11.816.816

Published: 2005

Journal Articles

Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin’s Disease.

Andreas Josting, MD, Jeremy Franklin, PhD, Michal Sieniawski, MD, Beate Pfistner, PhD, Thomas Schober, Hildtrud Nisters-Backes, Andreas Engert, MD, Volker Diehl, MD

Blood (2005) 106 (11): 818.

https://doi.org/10.1182/blood.V106.11.818.818

Published: 2005

Journal Articles

Elderly Patients with Early-Unfavorable Stage Hodgkin’s Disease (HD) Have a Poorer Outcome When Treated with Combined Modality Treatment and Extended Field Radiotherapy (EF): A Retrospective Analysis of the German Hodgkin Study Group.

Andreas Engert, MD, Heinz Haverkamp, Hans T. Eich, MD, Andreas Josting, MD, Beate Pfistner, Volker Diehl

Blood (2004) 104 (11): 1305.

https://doi.org/10.1182/blood.V104.11.1305.1305

Published: 2004

Journal Articles

Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG).

Andreas Josting, MD, Christian Rudolph, MD, Markus Mapara, MD, Jan-Peter Glossmann, MD, Markus Sieber, MD, Hartmut H. Kirchner, MD, Bernd Dörken, MD, Dieter K. Hossfeld, MD, Jens Kisro, MD, Bernd Metzner, MD, Wolfgang E. Berdel, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2004) 104 (11): 309.

https://doi.org/10.1182/blood.V104.11.309.309

Published: 2004

Journal Articles

Comparison of Patients (Pts) Characteristic and Treatment Outcomes in Lymphocyte-Predominant (LPHD) and Classical Hodgkin’s Disease (cHD): A Report from the German Hodgkin Lymphoma Study Group (GHSG).

Lucia Nogova, MD, Thorsten Reineke, Andreas Josting, MD, Karolin Behringer, MD, Beate Pfistner, PhD, Volker Diehl, MD, Andreas Engert, MD

Blood (2004) 104 (11): 1309.

https://doi.org/10.1182/blood.V104.11.1309.1309

Published: 2004

NARROW

Diagnosis and Treatment of MPN in Real Life - Interim-Analysis of an Exploratory Chart Review on 960 ET and MF Patients in Germany

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3 rd Interim Analysis of the German Non-Interventional Trial RISA

Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

A Prospectively Randomized Placebo-Controlled Trial of Epoetin-α in Patients with Advanced-Stage Hodgkin Lymphoma: Final Analysis of the GHSG HD15-EPO Trial

The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)

Late Events in Patients with Relapsed or Refractory Hodgkin’s Lymphoma Treated with an Autologous Stem Cell Transplantation.

Fertility in Male Hodgkin Lymphoma Patients - A Report of German Hodgkin Study Group.

Prognostic Factors and Treatment Outcome in Lymphocyte Predominant and Classical Hodgkin’s Lymphoma: A Comprehensive Analysis of the German Hodgkin Study Group.

Rituximab Added to an Intensified Salvage Chemotherapy Program Followed by Autologous Stem Cell Transplantation Improve in Relapsed and Refractory Aggressive Non-Hodgkin-Lymphoma.

A New BACOPP Schedule Is Feasible and Effective in Elderly Hodgkin’s Lymphoma Patients - Interim Results of a Multicenter Phase-II Trial of the German Hodgkin Study Group (GHSG).

Mortality during Treatment of Patients with Advanced Hodgkin’s Lymphoma Undergoing Dose Escalated BEACOPP Chemotherapy: An Analysis of the German Hodgkin Study Group (GHSG).

Leucopenia during Treatment Is a Good Prognostic Risk Factor for Patients Undergoing Chemotherapy for Hodgkin’s Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG).

Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).

Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma.

Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin’s Disease.

Elderly Patients with Early-Unfavorable Stage Hodgkin’s Disease (HD) Have a Poorer Outcome When Treated with Combined Modality Treatment and Extended Field Radiotherapy (EF): A Retrospective Analysis of the German Hodgkin Study Group.

Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG).

Comparison of Patients (Pts) Characteristic and Treatment Outcomes in Lymphocyte-Predominant (LPHD) and Classical Hodgkin’s Disease (cHD): A Report from the German Hodgkin Lymphoma Study Group (GHSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only